Elaine Colby, MD
Family Medicine · Birmingham, ALNPI 1609073972
Payments from drug & device makers
Across 319 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$845
- AstraZeneca$445
- Pfizer$407
- Boehringer Ingelheim$321
- AbbVie$293
- plus $874 from 19 others
What the payments were for
- Food & beverage$4,79399%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 122 | $1,641 |
| Lilly USA, LLC | 56 | $845 |
| AstraZeneca | 25 | $445 |
| Pfizer | 23 | $407 |
| Boehringer Ingelheim | 25 | $321 |
| AbbVie(2 entities) | 17 | $293 |
| Amgen | 7 | $103 |
| Radius Health, Inc. | 5 | $97 |
| GSK | 5 | $89 |
| Abbott | 4 | $74 |
| Amarin Pharma, Inc. | 5 | $66 |
| Novartis | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Astellas Pharma US Inc | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Bayer | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Corcept Therapeutics | 2 | $34 |
| Endogastric Solutions, Inc | 1 | $30 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Pulmonx Corporation | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$100
How this compares
$4,826 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $95,354 |
| MounjaroTirzepatide | 80 | $91,559 |
| EliquisApixaban | 61 | $44,167 |
| TrulicityDulaglutide | 41 | $43,277 |
| JardianceEmpagliflozin | 32 | $39,837 |
| JanuviaSitagliptin Phosphate | 15 | $17,930 |
| FarxigaDapagliflozin Propanediol | 19 | $15,641 |
| MyrbetriqMirabegron | 21 | $13,578 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $11,898 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,494 |
| LinzessLinaclotide | 14 | $11,383 |
| TrulancePlecanatide | 11 | $10,735 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,294 |
| GemtesaVibegron | 15 | $7,734 |
| Buprenorphine | 17 | $4,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $845 | $134,836121 claims |
| Novo NordiskOzempic | $1,641 | $95,35476 claims |
| PfizerEliquis | $407 | $44,16761 claims |
| Boehringer IngelheimJardiance | $321 | $39,83732 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $89 | $19,88848 claims |
| MerckJanuvia | $16 | $17,93015 claims |
| AstraZenecaFarxiga | $445 | $15,64119 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $13,57821 claims |
| AbbVieLinzess | $293 | $11,38314 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $48 | $10,73511 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $28 | $7,73415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Birmingham
- Michael VaughnBirmingham$9.9M
- Song YuBirmingham$1.7M
- Nova LawBirmingham$649K
- Lashelle BarmoreBirmingham$486K
- Scott WeisbergBirmingham$38K
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.